IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes

Rhea-AI Summary

IceCure (NASDAQ: ICCM) received a Notice of Allowance in China for a patent titled "Cryogen Flow Control" on Dec 5, 2025, covering temperature regulation for its next-generation XSense cryoablation system and probes.

The invention builds on prior intellectual property wins, with the same patent granted in Japan and pending in the EU, U.S., and other markets, and contributes to IceCure's stated 55 patents granted and allowed globally. The technology aims to use sensor-driven flow control to maintain distal tip temperatures, improve efficacy and tissue safety, and support navigation/mapping features. IceCure notes its ProSense cryoablation system has FDA marketing authorization for local treatment of low-risk breast cancer in specified patients.

Positive

• China patent Notice of Allowance for cryogen flow control
• Same invention granted in Japan
• 55 patents granted/allowed globally for cryoablation IP
• FDA marketing authorization for ProSense in low-risk breast cancer

Negative

• Key patent approvals still pending in EU and U.S.

Key Figures

Cryoablation patents 55 patents Global cryoablation IP portfolio cited by CEO

Patient age 70 years and older Indicated population for ProSense® low-risk breast cancer treatment

Market Reality Check

$0.6836 Last Close

Volume Volume 505,285 vs 20-day avg 375,346 (relative volume 1.35x) shows elevated trading ahead of this news. normal

Technical Price $0.6836 is trading below the 200-day MA of $1.02, reflecting a longer-term downtrend pre‑announcement.

Peers on Argus 1 Up

Within Healthcare/Medical Devices, several peers were up (LUNG +13.56%, VNRX +7.6%, BDMD +7.33%, APYX +2.4%) while ICCM was down 2.75% pre‑news and TELA slipped 3.04%, suggesting ICCM’s setup was more stock‑specific than a broad sector move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 19	Earnings & FDA update	Positive	-3.2%	Nine‑month results and highlight of ProSense® FDA marketing authorization.
Nov 18	Regulatory approval	Positive	+2.0%	Swissmedic approval for ProSense® in multiple cancer indications.
Nov 14	Listing compliance	Negative	-0.6%	Nasdaq notice for noncompliance with $1.00 minimum bid price rule.
Nov 12	Earnings date notice	Neutral	+2.5%	Announcement of upcoming financial and operating results call.
Nov 10	Management change	Positive	+4.6%	Promotion of Shay Levav to COO ahead of commercial ramp‑up.

Pattern Detected

Recent company‑specific positives (regulatory wins, management changes) often saw aligned or modestly positive reactions, while larger strategic/earnings updates have sometimes met with selling pressure.

Recent Company History

Over the last month, IceCure reported nine‑month results on Nov 19, 2025 featuring ProSense® FDA marketing authorization and a planned rollout to 30 U.S. sites, yet shares fell 3.21%. Swiss regulatory approval for ProSense® on Nov 18 saw a 2% gain. A Nasdaq minimum bid‑price notice on Nov 14 modestly pressured the stock, while a COO promotion on Nov 10 lifted shares 4.61%. Today’s China patent allowance adds another IP milestone on top of recent U.S. and Swiss regulatory progress.

Market Pulse Summary

This announcement adds a China patent allowance for cryogen flow control linked to IceCure’s next‑generation XSense™ system, expanding an IP portfolio totaling 55 patents. It builds on recent ProSense® FDA marketing authorization in low‑risk breast cancer and Swiss regulatory approval, reinforcing the company’s technology and geographic footprint. Investors may track how these protections translate into commercial adoption against a backdrop of prior Nasdaq minimum bid‑price notifications and a share price below the $1.02 200‑day MA.

Key Terms

regulatory approval regulatory

"cryoablation systems and probes already have regulatory approval in China"

Regulatory approval is the official permission given by government agencies or authorities that allows a product, service, or business activity to be legally operated or sold. It is important to investors because receiving approval often indicates that a product has been reviewed for safety and compliance, which can influence its success and the company’s prospects in the market. Without this approval, launching or selling certain products may be restricted or prohibited.

AI-generated analysis. Not financial advice.

Cryogenic flow control enhances the efficacy and precision of cryoablation procedures

Robust IP portfolio becomes increasingly strategic as global interest in IceCure's  platform and next-generation cryoablation technologies grows following ProSense®'s recent FDA marketing authorization in low-risk breast cancer

CAESAREA, Israel, Dec. 5, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced it received a Notice of Allowance for a patent from the China National Intellectual Property Administration for its invention titled "Cryogen Flow Control" which relates to its next-generation XSense™ cryoablation system and probes.

A patent for this invention has been granted in Japan and is currently pending approval in the European Union, the U.S., and other major markets.

"We believe IceCure's commitment to technology innovation and our drive to make a significant impact on patient outcomes has resulted in our intellectual property portfolio in cryoablation reaching 55 patents granted and allowed across the globe," said Eyal Shamir, IceCure's Chief Executive Officer. "Our cryoablation systems and probes already have regulatory approval in China for indications including breast cancer, and we continue to innovate next-generation liquid nitrogen-based systems including XSense™ to further improve patient outcomes."

The notice of allowance for the patent addresses precise temperature control, which is crucial for efficacy and tissue safety in cryoablation procedures. Cryogenic flow control achieves this by utilizing sensor data to regulate the flow of cryogens, ensuring the desired temperature is reached and maintained at the distal tip of catheters and probes. This optimized cryogenic delivery enhances treatment effectiveness in cryoablation procedures. Advanced cryogen flow control systems may also offer functionalities, such as navigation and mapping support within the patient's anatomy, and be incorporated into a wide range of cryosurgical tools.

The ProSense® Cryoablation System is the first and only medical device to receive U.S. Food and Drug Administration ("FDA") marketing authorization for the local treatment of low-risk breast cancer with adjuvant endocrine therapy for women aged 70 and older, including patients who are not suitable for surgical alternatives for breast cancer treatment. A full list of benefits and risks can be found on the Company's website. XSense™ is the Company's next-generation cryoablation system.

About IceCure Medical

IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and Asia.

Forward Looking Statement

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses: the pending approval of patents in the European Union, the United States and other major markets; its belief that commitment to technological innovation and its drive to make a significant impact on patient outcomes have contributed to the growth of its intellectual property portfolio; the expected benefits and performance of its next-generation XSense™ cryoablation system; its plans to continue innovating liquid nitrogen-based cryoablation technologies; the anticipated enhancement of treatment effectiveness and patient outcomes; and the potential future functionalities of cryogenic flow control systems across a wide range of cryosurgical tools. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC on March 27, 2025, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914

Logo: https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg

 

 

View original content:https://www.prnewswire.com/news-releases/icecure-receives-notice-of-patent-allowance-in-china-for-a-novel-cryogen-flow-control-to-optimize-patient-cryoablation-outcomes-302633981.html

SOURCE IceCure Medical

FAQ

What did IceCure announce on December 5, 2025 regarding patents for ICCM?

IceCure announced a Notice of Allowance in China for a "Cryogen Flow Control" patent tied to its XSense system.

How many patents does IceCure (ICCM) report globally after the China allowance?

The company reports 55 patents granted and allowed globally across its cryoablation portfolio.

Has the cryogen flow control patent been approved in other countries for ICCM?

The invention was granted in Japan and is pending in the EU, the U.S., and other markets.

What clinical or regulatory milestone does IceCure note alongside the patent news for ICCM?

IceCure highlights that its ProSense system received FDA marketing authorization for local treatment of low-risk breast cancer in specified patients.

What clinical benefit does the Cryogen Flow Control patent claim to provide for ICCM devices?

The patent targets precise temperature control at probe tips using sensor-driven cryogen flow to improve efficacy and tissue safety.